Contineum’s J&J-partnered M1 antagonist flunks another trial on September 16, 2026 Contineum Therapeutics Depressive disorder Johnson & Johnson M1 receptor antagonist Montgomery-Asberg Depression Rating Scale Questionnaire MOONLIGHT-1 Multiple Sclerosis Phase 2 trial PIPE-307 +